A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ITI 214 (Primary)
- Indications Cognition disorders; Heart failure; Parkinson's disease
- Focus Pharmacodynamics
- Sponsors Intra-Cellular Therapies
- 26 Jul 2018 Planned End Date changed from 1 Apr 2019 to 1 Jun 2019.
- 26 Jul 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2019.
- 26 Jul 2018 Status changed from not yet recruiting to recruiting.